13058_2017_807_MOESM2_ESM.docx (17.45 kB)

Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

Download (17.45 kB)
journal contribution
posted on 10.02.2017 by Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, HervĂŠ Bonnefoi, Matthew Squires, Yong Zhang, Stephanie Deudon, Michael Shi, Fabrice AndrĂŠ
Dose changes and dose delays by treatment arm. Table S2. Adverse events leading to study drug discontinuation regardless of study drug relationship. Table S3. Study center. (DOCX 17 kb)


Novartis Pharmaceuticals Corporation